BOSTON, March 23, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, in collaboration with teams from, Massachusetts General Hospital, Michigan State University and Northeastern University, published an article in the journal Cancers titled, Clinical Applications of Short Non-Coding RNA-Based Therapies in the Era of Precision Medicine. The article was published on March 21, 2022.
The article describes the development, challenges, and clinical successes of short RNA-based drugs and details several examples of how these RNA drugs are designed, chemically modified, and delivered for treatment of cancer, cardiovascular disease, and rare genetic disorders. In addition, the article highlights key similarities and differences between various short non-coding RNA platforms and discusses considerations to maximize treatment efficacy of RNA-based therapeutics. TransCode Co-Founder and scientific advisor, Dr. Anna Moore, was a contributing author to the article.
“The field of RNA therapeutics has matured to the point of clinical translation and is poised to transform the way we treat disease over the next decade,” commented Dr. Zdravka Medarova, Co-Founder and Chief Technology Officer of TransCode. “This report provides a snapshot of the field of RNA therapeutics and outlines the future for short non-coding RNAs as a therapeutic platform for a broad range of disorders, including cancer.”
TransCode’s CEO, Michael Dudley, added, “We believe RNA-based drugs will play an increasingly important role in personalized treatment for cancer and other diseases. Our first-in-human clinical trial which we intend to initiate later this year with our lead therapeutic candidate, targets an RNA molecule that has been shown to be the driver of metastatic disease. Since our proprietary delivery system has been engineered to deliver RNA therapeutics inside tumor cells, it has the potential to overcome the challenges of RNA delivery to a range of genetic targets. We believe this would represent a major step forward in unlocking therapeutic access to genetic targets involved in a range of cancers.
This article in Cancers further supports the potential of our platform of drug candidates and reaffirms our belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics.”
About TransCode Therapeutics
TransCode is an RNA oncology company created on the belief that cancer can be defeated using RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totaling over nine million per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. Two of the Company’s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on treating tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing other therapeutic candidates and diagnostic products related to its planned therapeutics business.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the timing and outcome of expected regulatory filings and clinical trials, including the filing of an eIND for the planned first-in-human study of TTX-MC138, statements concerning the timing and outcome of this study, including whether this study will demonstrate proof-of-concept, statements concerning patent applications, and statements concerning TransCode’s development programs and TTX technology platform generally. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk associated with drug discovery and development; the risk that the results of our planned clinical trials will not be consistent with our pre-clinical studies or expectations; risks associated with the timing and outcome of TransCode s planned regulatory submissions; risks associated with TransCode’s planned clinical trials for its product candidates; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; the risk of competition from other companies developing products for similar uses; risks associated with TransCode’s financial condition and its need to obtain additional funding to support its business activities, including TransCode’s ability to continue as a going concern; risks associated with TransCode’s dependence on third parties; and risks associated with the COVID-19 coronavirus. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause TransCode’s actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled “Risk Factors” in TransCode’s Quarterly Report on Form 10-Q for the period ended September 30, 2021, as well as discussions of potential risks, uncertainties and other important factors in any subsequent TransCode filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release; TransCode undertakes no duty to update this information unless required by law.
For more information, please contact:
TransCode Therapeutics, Inc.
Alan Freidman, VP Investor Relations
alan.freidman@transcodetherapeutics.com
Dave Gentry, CEO
RedChip Companies
Office: 1.800.RED.CHIP (733.2447)
Cell: 407.491.4498
RNAZ@redchip.com
